Arkolith/Insider Trading/TPTX/Form 4

Partridge Andrew John

EVP & Chief Commercial OfficerTurning Point Therapeutics, Inc. (TPTX) · full profile →Form 4 · filed Jul 15, 2021
Net Selling
Open-Market Buys
$0
Open-Market Sells
$140K
Net Open-Market Flow
-$140K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 14, 2021Sell(S)2K$74.90$140K22K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-21-046809) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML